Christopher Harmon, MD
MOHS-Micrographic Surgery · Vestavia Hls, ALNPI 1497791628
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 24 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 9 manufacturers reported payments, led by AbbVie at 37.3% of the total. Reporting peaked in 2024 at $278 and has fallen 59.0% since, to $114 in 2025.
Across 24 payments — averaging $31.15 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$279
- Organogenesis Inc.$269
- Amgen$56
- Regeneron Healthcare Solutions, Inc.$31
- Smith+Nephew$27
- LEO Pharma Inc.$25
- plus $60 from 3 others
What the payments were for
- Food & beverage$748100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 7 | $279 |
| Organogenesis Inc. | 8 | $269 |
| Amgen | 3 | $56 |
| Regeneron Healthcare Solutions, Inc. | 1 | $31 |
| Smith+Nephew | 1 | $27 |
| LEO Pharma Inc. | 1 | $25 |
| Boehringer Ingelheim | 1 | $22 |
| Sun Pharmaceutical Industries Inc. | 1 | $19 |
| DUSA Pharmaceuticals, Inc. | 1 | $19 |
How this compares
Too few mohs-micrographic surgery providers in Alabamato place this figure against a meaningful peer group, so we don't.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Mupirocin | 2,194 | $17,790 |
| Cephalexin | 1,808 | $6,519 |
| Doxycycline Hyclate | 337 | $2,091 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 265 | $748 |
| Fluconazole | 15 | $210 |
| Triamcinolone Acetonide | 14 | $170 |
| Azithromycin | 20 | $120 |
| Ketoconazole | 11 | $109 |
| Zolpidem Tartrate | 11 | $71 |
| Ciprofloxacin Hcl | 23 | $69 |
| Tramadol Hcl | 27 | $34 |
| Amoxicillin | 14 | $13 |
Paid to pharmacies, not to this prescriber.
Other mohs-micrographic surgery in Vestavia Hls
- Brian KingVestavia Hls$2K
- Gary MonheitBirmingham$37K
- Jeffrey StrickerDothan$10K
- Adam RichardsonNorthport$8K
- Albert RiveraMadison$6K
- Vernon ForresterMadison$4K
- Michael HadleyBirmingham$3K
- Scott FreemanMobile$3K
- Bailey TayebiBirmingham$3K
- Conway HuangBirmingham$3K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.